Pornpimol Charoentong
Overview
Explore the profile of Pornpimol Charoentong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
8666
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roberti M, Charoentong P, Lyu Y, Meyer M, Eichmuller S, Schmidt P, et al.
Oncoimmunology
. 2025 Feb;
14(1):2457793.
PMID: 39902862
T cells that recognize tumor-specific mutations are crucial for cancer immunosurveillance and in adoptive transfer of TILs or transgenic-TCR T cell products. However, their challenging identification and isolation limits their...
2.
Salek M, Forster J, Becker J, Meyer M, Charoentong P, Lyu Y, et al.
Mol Cell Proteomics
. 2024 Aug;
23(9):100825.
PMID: 39111711
Personalized cancer immunotherapies such as therapeutic vaccines and adoptive transfer of T cell receptor-transgenic T cells rely on the presentation of tumor-specific peptides by human leukocyte antigen class I molecules...
3.
Valous N, Popp F, Zornig I, Jager D, Charoentong P
Br J Cancer
. 2024 May;
131(2):205-211.
PMID: 38729996
Multi-omics experiments at bulk or single-cell resolution facilitate the discovery of hypothesis-generating biomarkers for predicting response to therapy, as well as aid in uncovering mechanistic insights into cellular and microenvironmental...
4.
Meyer M, Parpoulas C, Barthelemy T, Becker J, Charoentong P, Lyu Y, et al.
Front Immunol
. 2024 Jan;
14:1294565.
PMID: 38239352
Peptide-loaded MHC class I (pMHC-I) multimers have revolutionized our capabilities to monitor disease-associated T cell responses with high sensitivity and specificity. To improve the discovery of T cell receptors (TCR)...
5.
Lobentanzer S, Aloy P, Baumbach J, Bohar B, Carey V, Charoentong P, et al.
Nat Biotechnol
. 2023 Jun;
41(8):1056-1059.
PMID: 37337100
No abstract available.
6.
van Elsas M, Labrie C, Etzerodt A, Charoentong P, van Stigt Thans J, van Hall T, et al.
J Immunother Cancer
. 2023 Mar;
11(3).
PMID: 36914207
Background: Primary and secondary resistance is a major hurdle in cancer immunotherapy. Therefore, a better understanding of the underlying mechanisms involved in immunotherapy resistance is of pivotal importance to improve...
7.
Abdulrahman Z, Santegoets S, Sturm G, Charoentong P, Ijsselsteijn M, Somarakis A, et al.
J Immunother Cancer
. 2022 Feb;
10(2).
PMID: 35217577
Background: The composition of the tumor immune microenvironment (TIME) associated with good prognosis generally also predicts the success of immunotherapy, and both entail the presence of pre-existing tumor-specific T cells....
8.
Borst L, Sluijter M, Sturm G, Charoentong P, Santegoets S, van Gulijk M, et al.
Int J Cancer
. 2021 Oct;
150(4):688-704.
PMID: 34716584
The surface inhibitory receptor NKG2A forms heterodimers with the invariant CD94 chain and is expressed on a subset of activated CD8 T cells. As antibodies to block NKG2A are currently...
9.
Kortekaas K, Santegoets S, Tas L, Ehsan I, Charoentong P, van Doorn H, et al.
J Immunother Cancer
. 2021 Oct;
9(10).
PMID: 34716208
Background: A profound insight into the immune landscape of vulvar squamous cell carcinoma (VSCC) is lacking. Here, an in-depth interrogation of T cell infiltration, local immune contexture, signaling pathways and...
10.
Klebe M, Fremd C, Kriegsmann M, Kriegsmann K, Albrecht T, Thewes V, et al.
JCO Precis Oncol
. 2020 Sep;
4.
PMID: 32923902
Purpose: Conversion of tumor subtype frequently occurs in the course of metastatic breast cancer but is a poorly understood phenomenon. This study aims to compare molecular subtypes with subsequent lung...